New FDA Draft Rules Ease Approval for Alzheimer's Drugs

Sosei Offering: Company History, Earnings Structure, Business Model and Use of Proceeds

Healthcare Specialist

Winnie Wong

Equity Bottom-Up

<p><a href="https://www.smartkarma.com/entities/18033" target="_blank" data-smartkarma-citation="entities:18033:1">Actinogen Medical Ltd (ACW AU)</a> announced the <a href="https://www.asx.com.au/asxpdf/20180523/pdf/43v7b0fdjq6jrx.pdf" target="_blank">results of the Interim Analysis</a> of its Phase II XanADu trial that is conducted independently by the Data Safety and Monitoring Board (DSMB).  DSMB recommends continuing the XanADu study without modification.</p><p>The Interim Analysis was performed by the DSMB using prespecified assessments, outlined in the DSMB Charter and Study Protocol, of unblinded safety and efficacy patient data on the first 50 evaluable patients. This affirms the safety profile of the…</p>

Actinogen Medical Ltd (ACW AU) announced the results of the Interim Analysis of its Phase II XanADu trial that is conducted independently by the Data Safety and Monitoring Board (DSMB).  DSMB recommends continuing the XanADu study without modification.The Interim Analysis was performed by the DSMB using prespecified assessments, outlined in the DSMB Charter and Study Protocol, of unblinded safety and efficacy patient data on the first 50 evaluable patients. This affirms the safety profile of the…

Actinogen Releases Phase II Interim Result and Receives US Cornerstone Investment